Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial Comparing Laser TURP With and Without Dutasteride.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient is a male at least 50 years of age.~* The patient's peak urinary flow rate is at least 4 ml/sec, but not greater than 15 ml/sec, and the voided volume is at least 125 ml.~* Prostate volume must be greater than 30 grams~* The AUA-SI is greater than or equal to 9.~* Patient must be scheduled for a Laser TURP or eligible to be scheduled for Laser TURP~* Patient must be able to complete the study requirements prior to the scheduled laser TURP.~* The patient has signed the informed consent prior to the performance of any study procedures.~Exclusion Criteria:~* The patient has had any prior surgical intervention for BPH.~* The patient is receiving any intervention for prostate disease (either medical or surgical) or is presently enrolled in any study protocol.~* The patient has had a previous hypersensitivity, idiosyncrasy, or clinically suspected drug reaction to dutasteride.~* The patient has taken an alpha-1 blocker within 1 month of randomization.~* The patient has taken finasteride or dutasteride within 3 months of randomization.~* The patient has taken phenylephrine, pseudoephedrine, imipramine, and an anticholinergic or cholinergic medication within 4 weeks of the screening visit.~* The patient has taken an estrogen, androgen, or any drug producing androgen suppression, or anabolic steroids.~* The patient has an inability to urinate.~* The patient has clinically significant renal or hepatic impairment (i.e., creatinine greater than 2.0 mg/dl or AST greater than 1.5 times the upper limit of normal).~* The patient has a PSA level greater than 10 ug/ml (Hybritech).~* The patient requires the daily use of a pad or device for incontinence.~* The patient has had an episode of unstable angina pectoris, a myocardial infarction, transient ischemic attack, or a cerebrovascular accident within the past six months.~* The patient has a penile prosthesis or artificial urinary sphincter.~* The patient has a history or current evidence of carcinoma of the prostate or bladder, pelvic radiation or surgery, urethral stricture, prior surgery for BPH, or bladder neck obstruction.~* The patient has an active urinary tract disease or has undergone cystoscopy or biopsy of the prostate within two weeks prior to the first screening visit.~* The patient has known primary neurologic conditions such as multiple sclerosis or Parkinson's disease or other neurological diseases known to affect bladder function.~* The patient has had documented bacterial prostatitis within the past year.~* The patient has had two documented urinary tract infections of any type in the past year. A urinary tract infection is defined as \>100,000 colonies per ml urine from midstream clean catch or catheterized specimen.~* The patient has a severe bleeding disorder that makes laser TURP impossible.~* The patient must be able to stop any anticoagulant, NSAID or anti-platelet for 7 days prior to the laser TURP.~* The patient has had cancer that is not considered cured (except basal cell or squamous cell carcinoma of the skin). A patient is considered cured if there has been no evidence of cancer within five years of randomization.~* The patient has a diagnosis of a thought disorder (i.e., schizophrenia, bipolar disorder)~* The patient has any serious medical condition likely to impede successful completion of the study.~* The patient has a defibrillator that cannot be deactivated during laser TURP treatment.~* A bladder neck to verumontanum distance which is less than 30mm in length as measured by flexible cystoscopy and a total prostate volume \<25 ml or \>110 ml as measured by prostate volume ellipsoid formula during TRUS.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Laser TURP with dutasteride (Type: EXPERIMENTAL): Prior to and after standard treatment with laser TURP, dutasteride is applied to each patient
- Laser TURP with placebo (Type: PLACEBO_COMPARATOR): Prior to and after standard treatment with laser TURP, placebo is applied to each patient

Based on this trial design, predict the completion outcome and termination type (if applicable).